02394nam 2200625 a 450 991096512310332120251116221042.01-61728-630-3(CKB)2560000000068789(EBL)3020732(SSID)ssj0000467205(PQKBManifestationID)12192775(PQKBTitleCode)TC0000467205(PQKBWorkID)10489987(PQKB)10610926(MiAaPQ)EBC3020732(Au-PeEL)EBL3020732(CaPaEBR)ebr10680870(OCoLC)698081866(BIP)30334057(EXLCZ)99256000000006878920100419d2010 uy 0engur|n|---|||||txtccrBeneficial effects of perhexiline in cardiovascular disease states /Yuliy Y. Chirkov, Aaron L. Sverdlov and John D. Horowitz1st ed.New York Nova Biomedical/Nova Science Publishers20101 online resource (53 p.)Cardiology research and clinical developmentsDescription based upon print version of record.1-61668-977-3 Includes bibliographical references (p. [31]-38) and index.Clinical applications of perhexiline -- Pharmacokinetics and toxicity of perhexiline -- Pharmacology of perhexiline -- Conclusion and future perspectives.Perhexiline, 2-(2,2-dicyclohexylethyl) piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. This book discusses the benefits of perhexiline in the treatment of cardiovascular disease.Cardiology research and clinical developments series.PerhexilineTherapeutic useAngina pectorisChemotherapyCardiovascular agentsPerhexilineTherapeutic use.Angina pectorisChemotherapy.Cardiovascular agents.616.1/22061Chirkov Yuliy Y1869606Sverdlov Aaron L1869607Horowitz John D1869608MiAaPQMiAaPQMiAaPQBOOK9910965123103321Beneficial effects of perhexiline in cardiovascular disease states4477801UNINA